UA117768C2 - Офтальмологічний розчин тартрату бримонідину для місцевого застосування - Google Patents

Офтальмологічний розчин тартрату бримонідину для місцевого застосування

Info

Publication number
UA117768C2
UA117768C2 UAA201605897A UAA201605897A UA117768C2 UA 117768 C2 UA117768 C2 UA 117768C2 UA A201605897 A UAA201605897 A UA A201605897A UA A201605897 A UAA201605897 A UA A201605897A UA 117768 C2 UA117768 C2 UA 117768C2
Authority
UA
Ukraine
Prior art keywords
ophthalmic solution
brimonidine tartrate
tartrate ophthalmic
topical brimonidine
topical
Prior art date
Application number
UAA201605897A
Other languages
English (en)
Inventor
Мандар В. ШАХ
Діпак Бахрі
Original Assignee
Сентісс Фарма Прайвет Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сентісс Фарма Прайвет Лімітед filed Critical Сентісс Фарма Прайвет Лімітед
Publication of UA117768C2 publication Critical patent/UA117768C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

В даному винаході запропоновано водну офтальмологічну композицію, яка містить агоніст альфа-2-адренергічних рецепторів і неіоногенний целюлозний полімер, при цьому розчин має рН менше 6,5. В даному винаході також запропоновано водну офтальмологічну композицію, яка містить агоніст альфа-2-адренергічних рецепторів і галогенід бензододецинію. Також запропоновані способи виготовлення, застосування та спосіб зниження внутрішньоочного тиску у пацієнта, що цього потребує.
UAA201605897A 2013-12-24 2014-12-18 Офтальмологічний розчин тартрату бримонідину для місцевого застосування UA117768C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3763DE2013 2013-12-24
PCT/IB2014/067066 WO2015097600A2 (en) 2013-12-24 2014-12-18 Topical brimonidine tartrate ophthalmic solution

Publications (1)

Publication Number Publication Date
UA117768C2 true UA117768C2 (uk) 2018-09-25

Family

ID=52627534

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201605897A UA117768C2 (uk) 2013-12-24 2014-12-18 Офтальмологічний розчин тартрату бримонідину для місцевого застосування

Country Status (6)

Country Link
US (2) US10517869B2 (uk)
EP (1) EP3086776B1 (uk)
EA (1) EA030615B1 (uk)
ES (1) ES2818073T3 (uk)
UA (1) UA117768C2 (uk)
WO (1) WO2015097600A2 (uk)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180078500A1 (en) * 2015-03-19 2018-03-22 Allergan, Inc. Fixed dose combination of brimonidine and timolol
JP2019178083A (ja) * 2018-03-30 2019-10-17 参天製薬株式会社 点眼用水溶液
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
US20220273557A1 (en) * 2019-07-26 2022-09-01 Allergan Sales, Llc Compositions and methods for treatment of presbyopia
CN116421555A (zh) * 2023-04-27 2023-07-14 亚邦医药股份有限公司 一种酒石酸溴莫尼定滴眼液及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1463520A (en) 1974-09-06 1977-02-02 Pfizer Ltd Process for the production of imidazolines
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
BR0109317A (pt) * 2000-07-14 2003-06-17 Allergan Inc Composições contendo componentes agonistas alfa-2-adrenérgicos
CA2416169C (en) 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
CA2505836C (en) 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
US20090170944A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Ophthalmic micellar compositions with enhanced stability
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
CA3066050A1 (en) 2008-10-24 2010-04-29 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for dmd
WO2011027365A2 (en) 2009-09-07 2011-03-10 Micro Labs Limited Ophthalmic compositions containing dorzolamide, timolol and brimonidine
US9415048B2 (en) 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
CN107267517A (zh) 2011-04-22 2017-10-20 比奥马林技术公司 用于治疗、延缓和/或预防人类遗传性疾病如强直性肌营养不良症1型的新化合物
EP2704749A1 (en) 2011-05-05 2014-03-12 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
ES2935606T3 (es) 2011-12-08 2023-03-08 Sarepta Therapeutics Inc Análogos de oligonucleótidos dirigidos a LMNA humana
HUE036187T2 (hu) 2012-04-30 2018-06-28 Tillotts Pharma Ag Késleltetett leadású gyógyszerkészítmény

Also Published As

Publication number Publication date
WO2015097600A3 (en) 2015-10-29
EP3086776A2 (en) 2016-11-02
US20160331745A1 (en) 2016-11-17
WO2015097600A2 (en) 2015-07-02
EP3086776B1 (en) 2020-06-17
EA030615B1 (ru) 2018-08-31
ES2818073T3 (es) 2021-04-09
EA201690895A1 (ru) 2016-12-30
US20200129505A1 (en) 2020-04-30
US10517869B2 (en) 2019-12-31

Similar Documents

Publication Publication Date Title
UA117768C2 (uk) Офтальмологічний розчин тартрату бримонідину для місцевого застосування
PH12016501794A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
CL2016001041A1 (es) Implante intraocular biodegradable que contiene una matriz de polimero biodegradable, polietilenglicol 3350 y una prostamida; uso del mismo en la reducción de la presion ocular en el ojo de un mamifero; aparato para administrar el implante intraocular biodegradable; y método para confeccionar un implante intraocular biodegradable.
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
TR201905683T4 (tr) Aşındırıcı presbiyopi için oftalmik formülasyon ve yöntem.
EP2578622A3 (en) Enhanced oilfield swellable elastomers and methods for making and using same
BR112015022161A2 (pt) implante intraocular contendo prostamida
SG10201908928RA (en) Patient interface and aspects thereof
MX354544B (es) Composicion, en medio acuoso, que comprende al menos un acido hialuronico y al menos una sal hidrosoluble de octasulfato de sacarosa.
BR112018013008A2 (pt) produto médico de múltiplas camadas, e, método para preparação de um produto médico de múltiplas camadas.
MX2015010191A (es) Metodos para tratar infecciones microbianas, incluyendo mastitis.
NZ608202A (en) Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
PH12014502571A1 (en) Ophthalmic compositions with improved dessication protection and retention
CY1121841T1 (el) Τοπικη αντιμυκητιασικη συνθεση για τη θεραπεια της ονυχομυκητιασης
MX2016004673A (es) Composiciones y metodos para limpieza personal.
PH12016500565A1 (en) Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
BR112017012911A2 (pt) método para tratamento de insuficiência cardíaca
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
MX2012012978A (es) Metodo para producir pleurodesis.
MX2016007795A (es) Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales.
MX2016004058A (es) Sistemas y metodos para reducir la presion de tratamiento de fluidos de fracturamiento a base de carboximetilcelulosa reticulada.
MX2018004779A (es) Uso terapeutico de una solucion oftalmica acuosa esteril.
GB201020300D0 (en) Product
BR112015027707A2 (pt) Método de preparação de derivados de 3,5-bis(fluoroalquil)pirazole e compostos intermediários envolvidos nesse método
PH12016500418A1 (en) Aqueous liquid composition for solid material treatment